Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
#5PRI RANKED
Most Cited Paper
in Acute Myeloid Leukemia Research
18 Months Post-Publication
Class of 2026
“Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
Venetoclax plus hypomethylating agent therapy · European LeukemiaNet (ELN) risk classification · VIALE-A trial · TP53 mutation · FLT3 internal tandem duplication (FLT3-ITD) · NRAS mutation · KRAS mutation · adverse-risk AML · treatment-naive patients · Overall survival · Molecular signatures · bioinformatic algorithm · Risk stratification · ELN 2017 risk classification · ELN-2022 risk classification · placebo-azacitidine · higher-benefit group · intermediate-benefit group · lower-benefit group
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026. Accessed 2026-07-31. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459